1. Home
  2. CLBT vs STVN Comparison

CLBT vs STVN Comparison

Compare CLBT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellebrite DI Ltd.

CLBT

Cellebrite DI Ltd.

HOLD

Current Price

$17.17

Market Cap

4.5B

Sector

Technology

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$19.88

Market Cap

5.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLBT
STVN
Founded
1999
1949
Country
Israel
Italy
Employees
N/A
5521
Industry
Computer Software: Prepackaged Software
Containers/Packaging
Sector
Technology
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
5.4B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CLBT
STVN
Price
$17.17
$19.88
Analyst Decision
Strong Buy
Hold
Analyst Count
5
2
Target Price
$24.40
$23.75
AVG Volume (30 Days)
788.3K
294.8K
Earning Date
02-12-2026
03-05-2026
Dividend Yield
N/A
0.32%
EPS Growth
N/A
19.61
EPS
0.31
0.60
Revenue
$455,903,000.00
$1,373,219,524.00
Revenue This Year
$20.25
$8.42
Revenue Next Year
$17.24
$9.61
P/E Ratio
$54.32
$33.04
Revenue Growth
18.36
6.97
52 Week Low
$13.10
$17.81
52 Week High
$26.30
$28.00

Technical Indicators

Market Signals
Indicator
CLBT
STVN
Relative Strength Index (RSI) 38.39 38.77
Support Level $17.78 $20.19
Resistance Level $18.80 $21.23
Average True Range (ATR) 0.51 0.76
MACD -0.15 -0.00
Stochastic Oscillator 6.03 0.00

Price Performance

Historical Comparison
CLBT
STVN

About CLBT Cellebrite DI Ltd.

Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: